STL Volume 26 Number 6
3 POSTS 0 COMMENTSPurchase PDF for $2.79
A novel fixed combination lotion containing the super-potent corticosteroid halobetasol propionate 0.01% and retinoid tazarotene 0.045% (Duobrii™) has recently been introduced and indicated for the treatment of moderate to severe plaque psoriasis in adults.
Although biologics are well-studied, expertise regarding their use is often lacking. Many biologics have been added to the market in recent years with distinctive characteristics. This study was designed to create a tool to assist physicians involved in the care of patients with psoriasis undergoing biologic treatment.
The update covers Difelikefalin for IV use - Korsuva™ (Vifor Pharma, Cara Therapeutics), Topical MEK inhibitor - NFX-179 (NFlextion Therapeutics), Maralixibat oral solution - Livmarli™ (Mirum Pharmaceuticals), Ruxolitinib cream 1.5% - Opzelura™ (Incyte), Ruxolitinib tablets - Jakafi® (Incyte), and Avacopan capsules - Tavneos™ (ChemoCentryx).